"GLP-1 Alone Is Not Enough"... Big Pharma Seeks New Mechanisms for Obesity Drugs
Novo Nordisk Acquires Three Non-Incretin Candidates
Roche and Eli Lilly Compete for New Mechanisms
Addressing GLP-1 Limitations Such as Nausea Side Effects
Global pharmaceutical companies are now seeking the next growth engine for obesity treatments beyond glucagon-like peptide-1 (GLP-1). This shift is due to the fact that leading drugs like Wegovy and Mounjaro·Zepbound have demonstrated double-digit percentage weight loss, making it increasingly difficult for latecomers to differentiate themselves through similar mechanisms. As a result, pharmaceutical firms are targeting patients who do not respond sufficiently to GLP-1 or are racing to secure new mechanisms that improve tolerability and body composition.
According to the pharmaceutical and biotech industry on September 22, Novo Nordisk acquired three obesity drug programs from the US biotech company Calliope on September 18 (local time). All of these are non-incretin mechanism candidates, distinct from GLP-1 or gastric inhibitory polypeptide (GIP). The leading candidate, K-554, is a once-weekly peptide therapy that controls food intake through neural circuits different from those targeted by existing incretins. This candidate has been developed to a stage where it is ready for an Investigational New Drug (IND) application. Novo Nordisk also secured two small molecule candidates as part of this deal.
This is not the first time that Novo Nordisk, the developer of Wegovy, has turned its attention to mechanisms outside of incretins. Last year, the company acquired global rights (excluding the United States) to the oral obesity drug LX9851 from US-based Lexicon for up to 1 billion dollars (approximately 1.375 trillion won). This small molecule therapy targets ACSL5, which is involved in fat metabolism, and entered Phase 1 clinical trials earlier this year. The strategy is to further enhance the existing GLP-1 class while also expanding the portfolio with biological mechanisms that are completely different.
Competitors are taking similar steps. Roche signed a deal worth up to 5.3 billion dollars (approximately 7.288 trillion won) last year with Zealand Pharma to develop the amylin analog Petrelintide. Major pharmaceutical companies such as Eli Lilly are also working to secure candidates aimed at muscle preservation and body composition improvement. Non-incretin approaches encompass a broad range of biological pathways beyond incretins, including appetite regulation, fat metabolism, energy expenditure, and muscle preservation. Paradoxically, the driving force behind these trends is the very success of the GLP-1 class. As GLP-1 therapies have set a new efficacy benchmark for obesity drugs, differentiating subsequent therapies has become more challenging. Despite strong weight loss effects, there are gastrointestinal side effects such as nausea and vomiting, as well as variability in patient response. For latecomers, producing weight loss effects comparable to existing GLP-1 drugs is no longer sufficient to attract multi-billion dollar investments.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
In Korea, Hanmi Pharmaceutical is standing out. Hanmi’s HM17321 is a non-incretin obesity drug targeting UCN2, distinct from GLP-1. Its goal is to reduce fat mass while preserving or improving lean mass and muscle function. Last month, Roche’s subsidiary Genentech acquired the global rights to HM17321 (excluding Korea) for up to 2.3 billion dollars (about 3.2 trillion won). The industry believes that non-incretin therapies are more likely to supplement, rather than replace, GLP-1. These could be used in combination with GLP-1 for enhanced weight loss or could improve tolerability and body composition through alternative mechanisms. An industry insider commented, “It will become difficult to differentiate products solely based on percentage weight reduction. The key will be how widely we can cover patients who do not respond adequately to GLP-1 and how long-term the treatments can be sustained.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.